USFDA Recall of Indian Generic Drug Products: An In-Depth Analysis of Manufacturing Deficiencies, Regulatory Enforcement, and Risk Mitigation Approaches

India is the world's largest supplier of generic drugs and a major part of healthcare systems around the world, especially in the US. But the increasing number of drug recalls involving pharmaceuticals made in India has made regulators and public health experts nervous. This research critically examines recalls of generic drug items manufactured in India, emphasizing USFDA regulatory actions, recall classifications, and enforcement methods. A thorough examination of the primary causes of recalls, including microbiological and particle contamination, chemical impurities such as nitrosamines, potency variations, stability failures, labeling errors, data integrity breaches, cross-contamination, and supply chain issues. The research finds that Indian firms are more likely to be in recall databases than those from other nations. This is because they export a lot, have a lot of international inspections, and have a lot of trouble following good manufacturing procedures (GMP). The report also talks about ways to manage risk and emerging technology, such as digital quality systems, automation, and predictive analytics, that can help cut down on recalls and make global regulators more sure of Indian generic medications.